Empagliflozin Ameliorates Ouabain-Induced Na+ and Ca2+ Dysregulations in Ventricular Myocytes in an Na+-Dependent Manner

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker, Javed Butler, Gerasimos Filippatos et al. · New England Journal of Medicine · 2021 · 4.6K citations · Full text

Medicine, Cardiology, Pharmacology +14

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

Antonius Baartscheer, Cees A. Schumacher, Rob C. I. Wüst et al. · Diabetologia · 2016 · 652 citations · Full text

Medicine, Cardiology, Pharmacology +16

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation

Laween Uthman, Antonius Baartscheer, Boris Bleijlevens et al. · Diabetologia · 2017 · 600 citations · Full text

Medicine, Cardiology, Pharmacology +16

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction

Carlos G. Santos‐Gallego, Ariana P. Vargas-Delgado, Juan Antonio Requena-Ibáñez et al. · Journal of the American College of Cardiology · 2020 · 525 citations

Medicine, Cardiology, Pharmacology +12